These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 16229955)
1. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Smith MR Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071 [TBL] [Abstract][Full Text] [Related]
3. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804 [TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606 [TBL] [Abstract][Full Text] [Related]
6. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Saad F Cancer Treat Rev; 2008 Apr; 34(2):183-92. PubMed ID: 18061356 [TBL] [Abstract][Full Text] [Related]
7. Optimal management of metastatic bone disease. Major P Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294 [TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896 [TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Rosen LS Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692 [TBL] [Abstract][Full Text] [Related]
13. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Saad F; Lipton A Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486 [TBL] [Abstract][Full Text] [Related]
14. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Lein M; Miller K; Wirth M; Weissbach L; May C; Schmidt K; Haus U; Schrader M; Jung K Prostate; 2009 May; 69(6):624-32. PubMed ID: 19143027 [TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777 [TBL] [Abstract][Full Text] [Related]
16. Emerging strategies in bone health management for the adjuvant patient. Coleman RE Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485 [TBL] [Abstract][Full Text] [Related]
17. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Saad F Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691 [TBL] [Abstract][Full Text] [Related]
18. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Saad F; McKiernan J; Eastham J Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486 [TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. Saad F; Lipton A BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510 [TBL] [Abstract][Full Text] [Related]
20. Recommendations for zoledronic acid treatment of patients with bone metastases. Berenson JR Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]